atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 (Mar 4) ↗ Press ReleaseReaders might remember that atai shared topline results from a Phase 1 study of the candidate back in October 2023, finding the oral transmucosal film (OTF) formulation to be “well-tolerated with a favorable safety profile”. However, the company announced it would “further optimize” the candidate in preparation for a Phase 2 study in treatment-resistant depression.As such, this Phase 1b study will compare an improved OTF formulation of the candidate with IV. The improvements include taste masking, a backing layer, “and enhancements to further increase permeability.”For reference, atai dosed the very first subject with VLS-01 in Q4 2022.
Source link
Curtin University, Draslovka partner to advance glycine leaching technology
Reading Time: < 1 minute“The non-toxic amino acid has the potential to replace hazardous chemicals like cyanide in mineral
November 23, 2024
